argenx NV ADR (ARGX)vsArcutis Biotherapeutics Inc (ARQT)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
ARQT
Arcutis Biotherapeutics Inc
$23.89
+2.16%
HEALTHCARE · Cap: $3.00B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1046% more annual revenue ($5.32B vs $463.98M). ARGX leads profitability with a 32.3% profit margin vs 6.2%. ARGX trades at a lower P/E of 39.4x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ARQT
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Margin of Safety
+80.2%
Fair Value
$134.15
Current Price
$23.89
$110.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 59.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Trading at 13.6x book value
0.0% earnings growth
6.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : ARQT
The strongest argument for ARQT centers on Revenue Growth. Revenue growth of 59.3% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ARQT
The primary concerns for ARQT are Price/Book, EPS Growth, Profit Margin. A P/E of 108.6x leaves little room for execution misses.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ARQT is a hypergrowth play — different risk/reward profiles.
ARQT carries more volatility with a beta of 1.50 — expect wider price swings.
ARQT is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 47/100), backed by strong 32.3% margins and 59.3% revenue growth. ARQT offers better value entry with a 80.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Arcutis Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?